Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
BellBrook
Transcreener GDP FI Assay
CHF 0.00
In stock
BBL-3014-A200 assaysCHF 532.00
BBL-3014-1K1000 assaysCHF 794.00
BBL-3014-10K10000 assaysCHF 3'419.00
BBL-3014-100K10 x 10000 assaysINQ
Figure 1: Schematic overview of Transcreener GDP FI Assay.
| Product Details | |
|---|---|
| Product Type | Kit |
| Properties | |
| Application Set | Compound Screening |
| Crossreactivity | All |
| Quantity |
200 assays/96wells (BBL-3014-A) 1000 assays/384wells (BBL-3014-1K) 10000 assays/384wells (BBL-3014-10K) Note: The exact number of assays depends on enzyme reaction conditions. |
| Sensitivity | Excellent data quality (Z’ ≥ 0.7) at low substrate conversion (typically ≤10%). |
| Range | Accommodates GTP concentrations ranging from 0.1 μM to 1,000 μM. |
| Detection Type | Fluorescence intensity |
| Kit Contains |
GDP Antibody - IRDye® QC-1, GDP Alexa Fluor® 594 Tracer, Stop & Detect Buffer B, 10X, GTP, GDP Note: The plates are not included, please see manual for material not provided but necessary for assay. |
| Other Product Data |
Click here for Complete Information from the Original Manufacturer
Easy-to-Use (mix-and-read method), ultra-sensitive GTPase activity assay. HTS Compatible with 96, 384, and 1536-well plates. Tunable dynamic range to match the target of interest. Stable assay reagents - minimum 8-hour reagent and signal stability even at room temperature! Direct detection of GDP! |
| Declaration | Manufactured by BellBrook Labs. |
| Shipping and Handling | |
| Shipping | DRY ICE |
| Short Term Storage | -20°C |
| Long Term Storage | -20°C |
| Handling Advice | Avoid freeze/thaw cycles. |
| Documents | |
| Manual |
 Download PDF |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
The Transcreener® HTS Assay platform overcomes the need for time-consuming, one-off assay development for individual members within a group transfer enzyme family by utilizing a single set of assay reagents that detect an invariant product. The generic nature of the Transcreener® HTS Assay platform eliminates delays involved in assay development for new HTS targets, and greatly simplifies compound and inhibitor profiling across multiple target families. Transcreener assays have been validated with major HTS instruments to determine the optimal filters and settings for maximal assay performance. Application notes with all important details are available.
The Transcreener GDP GTPase assay is a homogenous, fluorescent immunoassay that monitors the activity of GTPases along with GEF and GAP partners. The assay directly measures the amount of GDP produced in an in vitro GTPase reaction. Three available fluorescent readouts, Fluorescence polarization (FP), Fluorescence intensity (FI) and Time-resolved Forster-resonance-energy-transfer (TR-FRET), provide a safe HTS-compatible alternative to cumbersome radioassay methods and are more sensitive and less subject to interference than colorimetric phosphate detection methods. All readouts use far-red tracers to minimize compound interference and lower false-positive rates.
The Transcreener® GDP FI Assay (Prod. No. BBL-3014) is a competitive immunoassay for GDP with a red fluorescent intensity (FI) readout. It can be used for screening GTPases, fucosyltransferase or mannosyltransferase and covers a broad range of GTP concentrations. Designed specifically for HTS and featuring a single addition mix-and-read format and room temperature reagent stability, the Transcreener® GDP FI Assay is compatible with plate readers typically found in research labs as well as those used in HTS core facilities. This assay accommodates GTP concentrations ranging from 0.1 μM to 1,000 μM with excellent data quality (Z’ ≥ 0.7) at low substrate conversion (typically ≤10%).
Product References
- Functional Comparison of Mx1 from Two Different Mouse Species Reveals the Involvement of Loop L4 in the Antiviral Activity against Influenza A Viruses: J. Verhelst, et al.; J. Virol. 89, 10879 (2015)
Related Products
